Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14725137 | 0.87 | ALDH1A1 (0.43) | ALDH1A1GAATSHRNPC1SMN1; SMN2 | |
| SCHEMBL4892582 | 0.79 | PPID (0.42) | ALDH1A1GRIN2BNPC1SMN1; SMN2 | |
| SCHEMBL13589885 | 0.79 | FUCA1 (0.49) | ALDH1A1GRIN2BNPC1SMN1; SMN2 | |
| SCHEMBL5651590 | 0.77 | GRIN2B (0.61) | GAAGRIN2BHRH3KCNH2TSHR | |
| SCHEMBL18017611 | 0.76 | HTT (0.45) | ALDH1A1TSHRKMT2ARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27940283 | 0.72 | GRIN2B (0.56) | ALDH1A1GAAGRIN2BHRH3MEN1 | |
| SCHEMBL4208603 | 0.71 | GRIN2B (0.55) | GRIN2BHRH3KCNH2TSHRKCNJ1 | |
| SCHEMBL3092297 | 0.71 | LMNA (0.47) | ALDH1A1CA1CA2MEN1KMT2A | |
| SCHEMBL5163838 | 0.71 | LMNA (0.47) | ALDH1A1CA1CA2MEN1KMT2A | |
| SCHEMBL9628053 | 0.69 | KCNH2 (0.73) | ALDH1A1HRH3KCNH2TSHRKCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026343-B2 | Pharmacologic inhibition of Myc function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-04-11 | — | — | US | claimed |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | claimed |
| WO-2003105759-A2 | PHARMACOLOGIC INHIBITION OF MYC FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-24 | — | — | WO | claimed |
| US-20190085404-A1 | METHODS OF IDENTIFYING AND TREATING IMMUNE CHECKPOINT INHIBITOR-RESPONSIVE NEOPLASMS AND CELLS, TRANSGENIC ANIMALS AND KITS FOR USE THEREIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-03-21 | — | — | US | disclosed |
| US-9155724-B2 | Combination methods for treatment of disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-10-13 | — | — | US | disclosed |
| US-8637556-B2 | Linked Myc-max small molecule inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2012055170-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | WO | disclosed |
| US-20120107317-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | US | disclosed |
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-01-19 | — | — | US | disclosed |
| WO-2010083404-A2 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-7026343-B2 | Pharmacologic inhibition of Myc function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | disclosed |
| WO-2003105759-A2 | PHARMACOLOGIC INHIBITION OF MYC FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | MYC, MAX, MYCBP | ALDH1A1 4780/4885GAA 2445/4885GRIN2B 3878/4885 |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | MYCBP, MYC, MYCBP2 | ALDH1A1 4614/4885GAA 2137/4885GRIN2B 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.